Bogart Wealth LLC’s Matinas BioPharma MTNB Stock Holding History

Bogart Wealth LLC’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1	Hold	2	–	–	﹤0.01%	2008
2026 Q1	$1	Buy	+2	New	+$1	﹤0.01%	1821

Other funds holding MTNB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Bogart Wealth LLC's MTNB Position: Q2 2026 in Review

Bogart Wealth LLC held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 2 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #2008.

Bogart Wealth LLC first reported a position in MTNB in Q1 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

Bogart Wealth LLC held 2 shares of Matinas BioPharma worth $1 as of Q2 2026.
Bogart Wealth LLC left its Matinas BioPharma share count unchanged in Q2 2026.
Matinas BioPharma made up ﹤0.01% of Bogart Wealth LLC's portfolio in Q2 2026, its #2008 holding.
Bogart Wealth LLC first reported a position in Matinas BioPharma in Q1 2026 and has held it in 2 quarters since.
25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.